Abstract
Live attenuated measles viruses of the Edmonston lineage (MV-Edm) have potent anti-tumor activity1,2,3,4 but are not entirely tumor-specific owing to widespread distribution of their native receptors, CD465,6 and SLAM7,8,9. We have therefore developed a pseudoreceptor system that allows rescue and propagation of fully retargeted viruses displaying single-chain antibody fragments. Viruses retargeted to tumor-selective CD38, epidermal growth factor receptor (EGFR) or EGFR mutant vIII (EGFRvIII) efficiently entered cells through their respective targeted receptors in vitro and in vivo, but not through CD46 and SLAM. When administered intratumorally or intravenously to mice bearing human CD38 or EGFR-positive human tumor xenografts, the targeted viruses demonstrated specific receptor-mediated anti-tumor activity. These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Peng, K.W. et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98, 2002–2007 (2001).
Peng, K.-W. et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62, 4656–4662 (2002).
Grote, D. et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97, 3746–3754 (2001).
Phuong, L.K. et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63, 2462–2469 (2003).
Dorig, R.E., Marcil, A., Chopra, A. & Richardson, C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295–305 (1993).
Naniche, D. et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67, 6025–6032 (1993).
Tatsuo, H., Ono, N., Tanaka, K. & Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406, 893–897 (2000).
Hahm, B. et al. Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule. J. Virol. 77, 3505–3515 (2003).
Schneider-Schaulies, S., Bieback, K., Avota, E., Klagge, I. & ter Meulen, V. Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunomodulation. J. Mol. Med. 80, 73–85 (2002).
McQuaid, S. & Cosby, S.L. An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab. Invest. 82, 403–409 (2002).
Nakamura, T. et al. Antibody-targeted cell fusion. Nat. Biotechnol. 22, 331–336 (2004).
Kaufmann, M. et al. Crystal structure of the anti-His tag antibody 3D5 single-chain fragment complexed to its antigen. J. Mol. Biol. 318, 135–147 (2002).
Masse, N., Barrett, T., Muller, C.P., Wild, T.F. & Buckland, R. Identification of a second major site for CD46 binding in the hemagglutinin protein from a laboratory strain of measles virus (MV): potential consequences for wild-type MV infection. J. Virol. 76, 13034–13038 (2002).
Hashimoto, K. et al. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J. Virol. 76, 6743–6749 (2002).
Andres, O., Obojes, K., Kim, K.S., ter Meulen, V. & Schneider-Schaulies, J. CD46- and CD150-independent endothelial cell infection with wild-type measles viruses. J. Gen. Virol. 84, 1189–1197 (2003).
Mehta, K., Shahid, U. & Malavasi, F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 10, 1408–1417 (1996).
Carpenter, G. Receptor tyrosine kinase substrates: src homology domains and signal transduction. FASEB J. 6, 3283–3289 (1992).
Kuan, C.T., Wikstrand, C.J. & Bigner, D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8, 83–96 (2001).
Schneider, U., Bullough, F., Vongpunsawad, S., Russell, S.J. & Cattaneo, R. Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol. 74, 9928–9936 (2000).
Hammond, A.L. et al. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 75, 2087–2096 (2001).
Bucheit, A.D. et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther. 7, 62–72 (2003).
Peng, K.-W., Holler, P., Orr, B., Kranz, D. & Russell, S.J. Targeting membrane fusion to specific peptide/MHC complexes through a high-affinity T-cell receptor. Gene Ther. 11, 1234–1239 (2004).
Wickham, T.J. Ligand-directed targeting of genes to the site of disease. Nat. Med. 9, 135–139 (2003).
Kasahara, N., Dozy, A.M. & Kan, Y.W. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373–1376 (1994).
Laquerre, S., Anderson, D.B., Stolz, D.B. & Glorioso, J.C. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 72, 9683–9697 (1998).
Kanerva, A. et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. 8, 449–458 (2003).
Schmitz, H., Wigand, R. & Heinrich, W. Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol. 117, 455–466 (1983).
Pollara, G., Katz, D.R. & Chain, B.M. The host response to herpes simplex virus infection. Curr. Opin. Infect. Dis. 17, 199–203 (2004).
Virgin, H.W., Dermody, T.S. & Tyler, K.L. Cellular and humoral immunity to reovirus infection. Curr. Top. Microbiol. Immunol. 233, 147–161 (1998).
Harrop, R., Ryan, M.G., Golding, H., Redchenko, I. & Carroll, M.W. Monitoring of human immunological responses to vaccinia virus. Methods Mol. Biol. 269, 243–266 (2004).
Douglas, J.T. et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. 17, 470–475 (1999).
Lorimer, I.A. & Lavictoire, S.J. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J. Immunol. Methods 237, 147–157 (2000).
Duprex, W., McQuaid, S., Hangartner, S., Billeter, M. & Rima, B. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J. Virol. 73, 9568–9575 (1999).
Radecke, F. et al. Rescue of measles viruses from cloned DNA. EMBO J. 14, 5773–5784 (1995).
Plemper, R.K., Hammond, A.L. & Cattaneo, R. Characterization of a region of the measles virus hemagglutinin sufficient for its dimerization. J. Virol. 74, 6485–6493 (2000).
Peng, K.W. et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum. Gene Ther. 14, 1565–1577 (2003).
Acknowledgements
We thank A. Plückthun for the generous gift of His scFv, J.A. Lust for CD38 scFv, G. Winter for EGFR scFv, J.P. Atkinson for CD46 plasmid, Y. Yanagi for CHO-SLAM cells and E. Vitetta for SKOV3ip.1 cells. This study is supported by the Mayo Foundation, Harold W. Siebens Foundation and National Institutes of Health grants CA100634-01.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Growth kinetics of ablated and retargeted viruses propagated on Vero cells. (PDF 87 kb)
Supplementary Fig. 2
In vivo stability of CD38-retargeted measles virus. (PDF 146 kb)
Rights and permissions
About this article
Cite this article
Nakamura, T., Peng, KW., Harvey, M. et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23, 209–214 (2005). https://doi.org/10.1038/nbt1060
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1060
This article is cited by
-
In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses
Cancer Gene Therapy (2020)
-
Hyaluronic acid pretreatment for Sendai virus-mediated cochlear gene transfer
Gene Therapy (2016)
-
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2 /neu or EpCAM as target receptors
Molecular Therapy - Oncolytics (2016)
-
Gene and virotherapy for hematological malignancies
International Journal of Hematology (2016)